Evolus Inc (NASDAQ:EOLS) has received an average rating of “Buy” from the eight brokerages that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $31.60.

Several research firms have recently weighed in on EOLS. Mizuho increased their price target on shares of Evolus from $25.00 to $29.00 and gave the company a “buy” rating in a research note on Tuesday, March 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of Evolus in a research note on Tuesday, March 19th. SunTrust Banks began coverage on shares of Evolus in a research note on Wednesday, March 20th. They issued a “buy” rating and a $30.00 price target for the company. Zacks Investment Research raised shares of Evolus from a “sell” rating to a “hold” rating in a research note on Monday, January 14th. Finally, Stifel Nicolaus began coverage on shares of Evolus in a research note on Monday, January 28th. They issued a “buy” rating and a $27.00 price target for the company.

Several hedge funds have recently modified their holdings of EOLS. Wells Fargo & Company MN lifted its holdings in shares of Evolus by 860.3% in the 3rd quarter. Wells Fargo & Company MN now owns 5,944 shares of the company’s stock worth $110,000 after acquiring an additional 5,325 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Evolus by 24.7% in the 3rd quarter. Alliancebernstein L.P. now owns 22,200 shares of the company’s stock worth $413,000 after acquiring an additional 4,400 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Evolus by 32.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 20,367 shares of the company’s stock worth $379,000 after acquiring an additional 5,005 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Evolus by 104.9% in the 3rd quarter. BlackRock Inc. now owns 615,719 shares of the company’s stock worth $11,465,000 after acquiring an additional 315,210 shares during the last quarter. Finally, Credit Suisse AG lifted its holdings in shares of Evolus by 70.4% in the 3rd quarter. Credit Suisse AG now owns 16,291 shares of the company’s stock worth $303,000 after acquiring an additional 6,730 shares during the last quarter. Hedge funds and other institutional investors own 19.56% of the company’s stock.

Evolus stock opened at $26.44 on Monday. Evolus has a 1-year low of $6.75 and a 1-year high of $39.50.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings results on Monday, March 18th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.09. On average, equities research analysts forecast that Evolus will post -3.45 EPS for the current fiscal year.

Evolus Company Profile

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Featured Article: What is cost of equity?

Analyst Recommendations for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.